Prime Medicine to Present at Three Major Biotech Conferences in March

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Prime Medicine will present at three major biotech conferences in March 2026, including TD Cowen and Citizens Life Sciences, with webcasts available afterward.

Prime Medicine to Present at Three Major Biotech Conferences in March

Prime Medicine has confirmed its participation in three prominent healthcare and biotechnology investor conferences scheduled for March 2026. The company's management team will engage with institutional investors through multiple formats, including fireside chat presentations and one-on-one meetings with portfolio managers and analysts.

The firm will present at the TD Cowen Health Care Conference and the Citizens Life Sciences Conference, where executives will participate in moderated fireside chats designed to discuss the company's pipeline, strategic initiatives, and market positioning. Additionally, Prime Medicine will host individual investor meetings at the Jefferies Biotech on the Beach Summit, providing opportunities for detailed discussions with selective institutional investors.

Webcasts of the fireside chat sessions will be made available on Prime Medicine's investor relations website, enabling broader access to the presentations for shareholders and market observers unable to attend the events in person. This investor engagement strategy is typical for biotech firms seeking to maintain ongoing communication with capital markets participants regarding company developments and financial performance.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 25

Related Coverage

Benzinga

Aethlon Medical Advances Hemopurifier Trial to Final Cohort After Safety Clearance

Aethlon Medical's Hemopurifier device advances to final clinical trial phase following positive safety review with no adverse events reported.

AEMD
GlobeNewswire Inc.

Quotient Therapeutics Lands $2.2B Merck Deal for IBD Drug Discovery Platform

Quotient Therapeutics and Merck partner on IBD drug discovery, with Quotient receiving $20M upfront and up to $2.2B in milestones.

MRK
GlobeNewswire Inc.

Zymeworks to Showcase Pipeline Progress at Major Healthcare Conferences

Zymeworks will present clinical and preclinical data at two major healthcare investor conferences in April, including the Needham Virtual Healthcare Conference and Bloom Burton & Co. event.

ZYME
GlobeNewswire Inc.

iDEL Therapeutics Names Ulbrich as Board Chair, Secures €9M Seed Round

iDEL Therapeutics appoints Dr. Claudia Ulbrich as Board Chair and secures €9M seed funding led by BiomedVC to advance its novel cancer drug delivery platform.

NVO
GlobeNewswire Inc.

Galapagos, Gilead in Advanced Talks on T-Cell Therapy Partnership

Galapagos and Gilead are in advanced partnership talks for a first-in-class T-cell engager for autoimmune diseases, with 50% cost-sharing and €500 million capital freed for Galapagos.

GILDGLPG
The Motley Fool

CRISPR Therapeutics Stock Slumps 9% Despite Casgevy Approval and Strong Cash Position

CRISPR Therapeutics stock declined 9% following a $585.2M convertible notes offering. The gene-editing company boasts FDA-approved Casgevy therapy and $1.8B in reserves but faces steep losses.

VRTXCRSP